Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22699558 | 0.85 | DNM1 (0.42) | EPHX1DNM1CA1CA2CA12 | |
| SCHEMBL31323004 | 0.80 | EPHX1 (0.44) | EPHX1DNM1ALDH1A1 | |
| SCHEMBL2335068 | 0.80 | ALDH1A1 (0.46) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL3190326 | 0.79 | EPHX1 (0.61) | EPHX1ALDH1A1USP2 | |
| SCHEMBL1979026 | 0.79 | TDP1 (0.55) | EPHX1DNM1CA1CA2CA12 | |
| SCHEMBL20123376 | 0.79 | DNM1 (0.41) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL22605262 | 0.79 | DNM1 (0.41) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL13525915 | 0.79 | ALDH1A1 (0.41) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL13037027 | 0.77 | EPHX1 (0.50) | EPHX1ALDH1A1CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL20149660 | 0.77 | PRMT3 (0.37) | EPHX1DNM1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734954-A1 | LIPID NANOPARTICLE FORMULATIONS FOR CELL THERAPY AND RELATED METHODS | Global Life Sciences Solutions Canada ULC (CA) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025005991-A1 | LIPID NANOPARTICLE FORMULATIONS FOR CELL THERAPY AND RELATED METHODS | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-01-02 | — | — | WO | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-8071764-B2 | Compounds of reverse turn mimetics and the use thereof (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-09 | — | — | US | disclosed |
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | MCL1, MYADM, FLT3 | EPHX1 3270/4885DNM1 3548/4885CA1 1138/4885 |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | GRIK5, CYP3A5, GRK5 | EPHX1 1297/4885DNM1 1334/4885CA1 2933/4885 |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | MCL1, BID, MYADM | EPHX1 3009/4885DNM1 3039/4885CA1 1224/4885 |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | EPHX1 4841/4885DNM1 785/4885CA1 4866/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | EPHX1 4841/4885DNM1 785/4885CA1 4866/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | EPHX1 4787/4885DNM1 339/4885CA1 4771/4885 |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | EPHX1 4841/4885DNM1 785/4885CA1 4866/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | EPHX1 1231/4885DNM1 1454/4885CA1 4725/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | EPHX1 1924/4885DNM1 3156/4885CA1 3677/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | EPHX1 4841/4885DNM1 785/4885CA1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.